TG Therapeutics, Inc. (TGTX) — Analysis Summary
TG Therapeutics, Inc. (TGTX) has a market cap of $7.96B with year-over-year revenue growth of +87.3%. Net margin stands at 72.6%. The stock trades at a P/E ratio of 17.2.
Key Takeaways
- Revenue changed +87.3% year-over-year
- Net margin of 72.6%
- P/E ratio of 17.2
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, TGTX posted revenue growth of +87.3% and trades at a P/E of 17.2.
TG Therapeutics, Inc. (TGTX)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Debt/EBITDA at 5.0x — elevated leverage
The latest filing shows negative free cash flow.
Operating cash flow is negative while net income remains positive.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
399
Headquarters
NEW YORK, NY
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.